Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
Journal of Medicinal Chemistry|March 19, 2004
Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor modelBalu N Balasubramanian, Denis R St Laurent, Mark G Saulnier, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2Jun Gong, Alain C Mita, Zihan Wei, et al.
Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1Jun Gong, Alain C Mita, Zihan Wei, et al.
Journal of Medicinal Chemistry|April 2, 2005
Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11Mark G Saulnier, Balu N Balasubramanian, Byron H Long, et al.
The New England Journal of Medicine|December 22, 2018
Sorafenib for Advanced and Refractory Desmoid TumorsMrinal M Gounder, Michelle R Mahoney, Brian A Van Tine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary CancerHeather J Chalfin, Tiziano Pramparo, Amir Mortazavi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor TherapyDaniel M Girardi, Scot A Niglio, Amir Mortazavi, et al.
The Lancet. Oncology|July 10, 2020
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trialAndrea B Apolo, Rosa Nadal, Yusuke Tomita, et al.
Pageof 15